** U.S.-listed shares of Merus NV MRUS.O down 6.3% to $58.50 post-market as co seeks equity raise
** Dutch biotech firm launches stock offering; targeted raise not disclosed
** Co plans to use net offering proceeds to advance clinical development of its product candidates, for preclinical research and technology development, and for working capital among other purposes
** Jefferies, BofA, Leerink, Guggenheim, Truist and LifeSci Capital are jt bookrunners
** On May 23, MRUS shares surged ~33% to close at $55.14 after co's lead candidate petosemtamab in combination with Merck's MRK.N Keytruda delayed progression of a type of head and neck cancer in a mid-stage trial
** MRUS shares on Tues finished up 6.6% at $62.42, up 50% over the past seven sessions
** Co has ~69.2 mln shares outstanding for $4.3 bln market cap
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。